JP2005500025A5 - - Google Patents

Download PDF

Info

Publication number
JP2005500025A5
JP2005500025A5 JP2003500106A JP2003500106A JP2005500025A5 JP 2005500025 A5 JP2005500025 A5 JP 2005500025A5 JP 2003500106 A JP2003500106 A JP 2003500106A JP 2003500106 A JP2003500106 A JP 2003500106A JP 2005500025 A5 JP2005500025 A5 JP 2005500025A5
Authority
JP
Japan
Prior art keywords
sirna molecule
sequence
nucleotide
sirna
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003500106A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005500025A (ja
Filing date
Publication date
Priority claimed from US10/138,674 external-priority patent/US7034009B2/en
Application filed filed Critical
Priority claimed from PCT/US2002/017674 external-priority patent/WO2002096927A2/en
Publication of JP2005500025A publication Critical patent/JP2005500025A/ja
Publication of JP2005500025A5 publication Critical patent/JP2005500025A5/ja
Pending legal-status Critical Current

Links

JP2003500106A 2001-05-29 2002-05-29 女性生殖疾病及び状態の核酸に基づく調節 Pending JP2005500025A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87016101A 2001-05-29 2001-05-29
US33446101P 2001-11-30 2001-11-30
US10/138,674 US7034009B2 (en) 1995-10-26 2002-05-03 Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
PCT/US2002/017674 WO2002096927A2 (en) 2001-05-29 2002-05-29 Ribozyme based treatment of female reproductive diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008149684A Division JP2009000106A (ja) 2001-05-29 2008-06-06 女性生殖疾病及び状態の核酸に基づく調節

Publications (2)

Publication Number Publication Date
JP2005500025A JP2005500025A (ja) 2005-01-06
JP2005500025A5 true JP2005500025A5 (https=) 2005-09-15

Family

ID=27385212

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003500106A Pending JP2005500025A (ja) 2001-05-29 2002-05-29 女性生殖疾病及び状態の核酸に基づく調節
JP2008149684A Pending JP2009000106A (ja) 2001-05-29 2008-06-06 女性生殖疾病及び状態の核酸に基づく調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008149684A Pending JP2009000106A (ja) 2001-05-29 2008-06-06 女性生殖疾病及び状態の核酸に基づく調節

Country Status (6)

Country Link
EP (1) EP1390385A4 (https=)
JP (2) JP2005500025A (https=)
AU (1) AU2002344237B8 (https=)
CA (1) CA2448320A1 (https=)
GB (1) GB0404461D0 (https=)
WO (1) WO2002096927A2 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030216335A1 (en) * 2001-11-30 2003-11-20 Jennifer Lockridge Method and reagent for the modulation of female reproductive diseases and conditions
US7491805B2 (en) * 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7833992B2 (en) * 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
EP1386004A4 (en) 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050014172A1 (en) 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en) * 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
FR2832154B1 (fr) * 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1432724A4 (en) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
AU2006203062B2 (en) * 2002-02-20 2009-03-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1495120B1 (en) 2002-04-18 2012-10-10 Acuity Pharmaceuticals, Inc Means and methods for the specific modulation of target genes in the eye
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
PL1897548T5 (pl) * 2003-02-28 2025-03-17 The Johns Hopkins University Regulacja komórek T
EP1606305A4 (en) * 2003-03-12 2009-06-24 Vasgene Therapeutics Inc NUCLEIC ACID COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH
EP1603535A4 (en) * 2003-03-18 2008-10-15 Ethicon Inc AROMATASE HEMMER DIAGNOSIS AND THERAPY
CA2528372A1 (en) * 2003-06-06 2005-01-27 Senesco Technologies, Inc. Inhibition of apoptosis-specific elf-5a ("eif-5a1") with antisense oligonucleotides and sirnas as anti-inflammatory therapeutics
EP1660657A1 (en) 2003-08-28 2006-05-31 Novartis AG Interfering rna duplex having blunt-ends and 3'-modifications
WO2005038013A1 (en) 2003-10-07 2005-04-28 Isis Pharmaceuticals, Inc. Artisense oligonucleotides optimized for kidney targeting
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
WO2005076998A2 (en) * 2004-02-05 2005-08-25 Intradigm Corporation Rnai therapeutics for treatment of eye neovascularization diseases
ATE452188T1 (de) 2004-02-10 2010-01-15 Sirna Therapeutics Inc Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid)
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
CA2572223C (en) * 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
CA2583826A1 (en) * 2004-10-22 2006-05-04 Benitec, Inc. Therapeutic rnai agents for treating psoriasis
US20090010907A1 (en) * 2004-12-14 2009-01-08 National Institute Of Immunology Dnazymes for Inhibition of Japanese Encephalitis Virus Replication
WO2006087722A1 (en) * 2005-02-17 2006-08-24 Hadasit Medical Research Services And Development Ltd. Bisphosphonates for treating endometriosis
CN101277704A (zh) 2005-04-12 2008-10-01 因特拉迪格姆公司 用于治疗癌症及其它新血管生成疾病的RNAi治疗剂的组合物和方法
US7893244B2 (en) 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
JP2009537606A (ja) * 2006-05-25 2009-10-29 ノバルティス アクチエンゲゼルシャフト チロシンキナーゼ阻害剤
US7872118B2 (en) 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
AU2009322279A1 (en) 2008-12-04 2011-07-14 Opko Pharmaceuticals, Llc Compositions and methods for selective inhibition of pro-angiogenic VEGF isoforms
WO2011019423A2 (en) 2009-05-20 2011-02-17 Schering Corporation Modulation of pilr receptors to treat microbial infections
JP5833549B2 (ja) 2009-06-22 2015-12-16 アンピオ ファーマシューティカルズ，インコーポレイテッド 血管透過性亢進を抑制するためのダナゾールを含む製薬組成物
EP2475388B1 (en) 2009-09-10 2017-11-08 Merck Sharp & Dohme Corp. Use of il-33 antagonists to treat fibrotic disease
EP2513308B1 (en) 2009-12-17 2017-01-18 Merck Sharp & Dohme Corp. Modulation of pilr to treat immune disorders
MX2013000986A (es) 2010-07-28 2013-07-03 Alcon Res Ltd Sirna dirigido al vegfa y metodos de tratamiento in vivo.
US9243246B2 (en) 2010-08-24 2016-01-26 Sirna Therapeutics, Inc. Single-stranded RNAi agents containing an internal, non-nucleic acid spacer
NZ607996A (en) 2010-09-22 2014-07-25 Alios Biopharma Inc Substituted nucleotide analogs
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
CN104968350A (zh) 2012-12-19 2015-10-07 安皮奥制药股份有限公司 疾病的治疗方法
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
EP3895724B1 (en) 2013-05-22 2025-06-25 Zensun (Shanghai) Science and Technology, Co., Ltd. Extended release of neuregulin for treating heart failure
CN103627709A (zh) * 2013-12-06 2014-03-12 孙仑泉 抑制血管内皮生长因子受体基因表达的脱氧核酶
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
WO1999004819A1 (en) * 1997-07-24 1999-02-04 Inex Pharmaceuticals Corporation Liposomal compositions for the delivery of nucleic acid catalysts
WO2003070910A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

Similar Documents

Publication Publication Date Title
JP2005500025A5 (https=)
JP2005517452A5 (https=)
JP2005524393A5 (https=)
Suparpprom et al. Perspectives on conformationally constrained peptide nucleic acid (PNA): insights into the structural design, properties and applications
JP2005517436A5 (https=)
JP2005517430A5 (https=)
JP2005517427A5 (https=)
JP2005517432A5 (https=)
EP1097939B1 (en) Method for the synthesis of isoguanosine and of its 2'-derivatives
JP2006502694A5 (https=)
JP2003505108A (ja) 転写フリーｓｅｌｅｘ
JP2005518803A5 (https=)
JP2008283975A5 (https=)
JP2003511016A (ja) オリゴヌクレオチドを補充する高親和性ｒｎアーゼｈの設計
JP2005517438A5 (https=)
JP2007529224A5 (https=)
JP2005517433A5 (https=)
JP2010533499A5 (https=)
NZ599237A (en) Sirna compounds comprising terminal substitutions
CA2457528A1 (en) Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina)
JP2009514877A5 (https=)
JP2002531053A5 (https=)
JPH06511492A (ja) キラルリン結合を有するオリゴヌクレオチド
JP2005522997A (ja) 交代セグメントを含むオリゴヌクレオチド及びその用途
JP7033591B2 (ja) 治療用オリゴヌクレオチドの捕捉および検出